Data supporting figures, tables and supplementary information in the published article: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Name: Data supporting figures, tables and supplementary information in the published article: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Creator: Ren, Lili; Chen, Jieyong; Wang, Jianwei; Guo, Li; Ou, Xiuyuan; Xiang, Zichun; Liu, Yan; Lei, Xiaobo; Mu, Zhixia; Li, Pei; Chen, Ting; Hu, Keping; Mi, Dan; Hu, Jiaxin; Chen, Xing; Qian, Zhaohui; Guo, Ruixuan; Jin, Qi
Published: 2020-03-26T00:00:00+08:00

Figshare2024-02-23 更新2026-04-08 收录

病毒进入机制

交叉免疫反应

数据链接：

https://springernature.figshare.com/articles/dataset/Data_supporting_figures_tables_and_supplementary_information_in_the_published_article_Characterization_of_spike_glycoprotein_of_SARS-CoV-2_on_virus_entry_and_its_immune_cross-reactivity_with_SARS-CoV/11954889/1 数据链接链接失效反馈

官方服务：

资源简介：

This dataset comprises a single Excel .xlsx spreadsheet with 29 tabs. The data are western blot images and quantitative data characterising spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. The data underlie the figures, table and supplementary figures of the related manuscript. The 29 tabs are as follows. (NOTE: Western blot images do not display in figshare viewer: please download the spreadsheet to view these)- Western blots for incorporation of SARS-CoV-2 S protein into pseudovirions.(Figure 1B, Figure 1C, Figure 1D, Figure 1E, Figure 1F, Figure 1G, Figure 1H, Figure 1I, Figure 1J)- Entry and receptor of SARS-CoV-2 S pseudovirons.(Figure 2A, Figure 2B, Figure 2D)- Endocytosis of SARS-CoV-2 S pseudovirions on 293/hACE2 cells.(Figure 3A, Figure 3B, Figure 3C, Figure 3D, Figure 3E, Figure 3F)- Activation of SARS-CoV-2 S protein by cathepsin and trypsin.(Figure 4A, Figure 4C, Figure 4D, Figure 4E)- Characterization of polyclonal rabbit anti-SARS S1 antibodies T62.(Figure 5B, Figure 5E)- Limited cross-neutralization of SARS-CoV and COVID-19 sera.(Figure 6A, Figure 6B)- Neutralization activities of antisera from SARS-CoV and COVID-19 patients.(Table 1)- Treatment of cells with 130, a TRPML1 inhibitor.(Supplementary Figure 1)- Expressing type II membrane serine protease (TMPRSS) 2, 4, 11A, 11D, and 11E on 293/hACE2 cells.(Supplementary Figure 3). In the related publication, the authors use a lentiviral pseudotype system and determine cell type susceptibility, virus receptor, entry pathway and protease priming for SARS-CoV-2. They also identify several potential drug targets for SARS-CoV-2.

提供机构：

Ren, Lili; Chen, Jieyong; Wang, Jianwei; Guo, Li; Ou, Xiuyuan; Xiang, Zichun; Liu, Yan; Lei, Xiaobo; Mu, Zhixia; Li, Pei; Chen, Ting; Hu, Keping; Mi, Dan; Hu, Jiaxin; Chen, Xing; Qian, Zhaohui; Guo, Ruixuan; Jin, Qi

创建时间：

2020-03-26